![HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06512 ELISA.jpg&file=scm_files/productFile_notes/2025/04/25/Z06512 ELISA.jpg)
Immobilized HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/Well) on streptavidin(5 μl/ml) precoated plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 7.7 ng/ml determined by ELISA.
![HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06512 HPLC.png&file=scm_files/productFile_notes/2025/04/25/Z06512 HPLC.png)
The purity of HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.
![HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06512 PAGE.png&file=scm_files/productFile_notes/2025/04/25/Z06512 PAGE.png)
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
![HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06512 Blocking.jpg&file=scm_files/productFile_notes/2025/06/05/Z06512 Blocking.jpg)
Serial dilutions of Anti-NKG2A Antibody were added into HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human, His Tag : Human NKG2A&CD94, mFc Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 0.15 μg/ml.
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer[Biotin], His & Avi, Human
Z06512 | |
|
|
¥315,258.00 | |
|
|
|
|
Ask us a question |